TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00114608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Focus™ Neuromuscular Stimulation System
Description: Electrical foot stimulation was produced by surface electrodes placed on the sole of the foot over the plantar muscle group. Electrical stimulation was delivered by The Focus™ Neuromuscular Stimulation System, Empi, Inc. (St. Paul, MN.) The crucial stimulus parameters were: biphasic symmetrical square wave at 50 pulses per second, phase duration of 300 microseconds, a starting ramp up time of 2 seconds and a finishing ramp down time of 2 seconds per stimulation cycle, and a stimulation cycle of 12 seconds on and 48 seconds off per minute. Stimulation was increased to an intensity just sufficient to create a slight visible muscle twitch. This level of intensity caused no evident discomfort in any of the subjects in our first study. Subjects were continually monitored throughout this study for any indication of discomfort.The Focus™ Neuromuscular Stimulation System created electrical stimulation of the plantar foot muscles.
Study: NCT01737099

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA-O

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02395133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW).
Study: NCT03737084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCT Intervention
Description: The training consists of six weekly sessions. The participant will receive six guided meditation audio, relative to each session, to practice during the week.
Study: NCT02491190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMPOWER Educational Module
Description: Evidence-based video module delivering content of the Right Question intervention from Deen et al. (2011)
Study: NCT00722501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ERB-257

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00962247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Television reduction device
Description: A TV allowance helps turn off the television when the time limits have been met.
Study: NCT04040257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team-based approach
Description: Team-based participation in the The Perinatal Quality Foundation Fetal Monitoring Credentialing (PQF/FMC) exam.
Study: NCT04235790

Intervention type: DEVICE
Group type: OTHER
Intervention: Eye Tracking Device
Description: Eye tracking glasses
Study: NCT00627900

Intervention type: DEVICE
Group type: OTHER
Intervention: bare metal stent
Description: implantation of a bare metal stent

Intervention type: DEVICE
Group type: OTHER
Intervention: Cypher-Stent (Implantation of a sirolimus-eluting stent)
Description: Implantation of a sirolimus-eluting stent
Study: NCT01906671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xaluprine
Description: Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xaluprine
Description: Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Puri-Nethol
Description: Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
Study: NCT01338402

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phemfilcon A contact lens with color
Description: Hydrogel contact lens with color
Study: NCT04810000

Intervention type: DEVICE
Intervention: tourniquet
Description: Tourniquet release before/after wound closure

Intervention type: DEVICE
Intervention: tourniquet
Description: Tourniquet release before/after wound closure
Study: NCT01011530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN4924
Description: Patients will be administered MLN4924 via an IV infusion. Each 21-day treatment cycle is composed of 2 weeks intermittent dosing of MLN4924 on Days 1, 4, 8 and 11, followed by a rest period of 10 days. A cohort of patients will receive a reduced first dose on Day 1, approximately half the strength of the dose received on Days 4, 8, 11 and dose will not be administered on Day 4 if the Day 1 dose is not tolerated.(Schedule A ramp-up), or continuous weekly dosing (Days 1, 8, and 15) of MLN4924 (Schedule B)
Study: NCT02935361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC
Study: NCT00713791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: Treatment period 1: 10mg oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: Treatment period 2: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
Study: NCT01906671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Puri-Nethol
Description: Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
Study: NCT02569710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: ODV capsules will be administered in a dose range of 25 to 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: ODV capsules will be administered in a dose range of 25 to 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: ODV capsules will be administered in a dose range of 25 to 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: ODV capsules will be administered in a dose range of 25 to 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: ODV capsules will be administered in a dose range of 25 to 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: ODV capsules will be administered in a dose range of 25 to 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: ODV capsules will be administered in a dose range of 25 to 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: ODV capsules will be administered in a dose range of 25 to 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV)
Description: SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV)
Description: SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).
Study: NCT00713791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: Treatment period 3: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: Treatment period 4: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
Study: NCT06496685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducational
Description: A structured AAT program and usual treatment in Experimental group.
Study: NCT02569710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV)
Description: SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV)
Description: SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV)
Description: SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV)
Description: SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).
Study: NCT02503267

Intervention type: OTHER
Intervention: none intervention
Study: NCT01423396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: optimal care of VRF
Description: VRF of AD patients will be treated optimally in strict compliance with the French HAS guidelines concerning targets for blood pressure, glycaemia and blood lipid levels, in accordance with standardized therapeutic regimens.

Intervention type: OTHER
Group type: OTHER
Intervention: standard care
Description: AD patients will be followed with the city doctor and the letter t will be send for remember French HAS guidelines
Study: NCT02064270

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single-Use Negative Pressure Wound Therapy
Description: Application of PICO Single-Use Negative Pressure Wound Therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard postsurgical dressings
Description: Use of Standard postsurgical dressings
Study: NCT05484856

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose tissue derived stromal cells
Description: autologous adipose tissue derived stromal cells is recovered as pellet after non enzymatic processing with sonication using ultrasound . This isolation process yielded an abundant population of Adipose stromal cells(ASCs) which have multipotent differentiation potential. Immunophenotype is a CD14-, CD29+, CD31-, CD34low/+, CD45-, CD73+ and CD105+ , the SVF represents the 50-70% in volume of a lipoaspirate specimen. The SVF hosts a heterogeneous cell population (110x103 cells/ml on average) comprising mainly CD105+ mesenchymal stem cells (MSC,2-- 20%), plus a wide number of CD34+ hematopoietic cells (40%)
Study: NCT01553604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: augmentation mammaplasty
Description: Dressing is removed on the first postoperative day
Study: NCT03732625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: DTG will be replaced by Raltegravir (RAL) 1200 QD, maintaining the other two drugs that constituted the triple therapy established before the inclusion of the patient in the study.
Study: NCT03474549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tigertriever revascularization device
Description: Mechanical Thrombectomy
Study: NCT01416233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous fat grafting to the orbit
Description: subjects will undergo fat harvesting followed by autologous fat grafting into the orbit into their anophthalmic orbit
Study: NCT01933022

Intervention type: DRUG
Group type: OTHER
Intervention: Eligard
Description: Subcutaneous Injection
Study: NCT01407211

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin A
Description: 25000 IU/day vitamin A 6 months~1 Cap/Day~1 cap placebo/day for 6 month
Study: NCT01553604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: augmentation mammaplasty
Description: Dressing is removed on the 6th postoperative day
Study: NCT01407211

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin A
Description: 25000 IU/day vitamin A 6 months~1 Cap/Day~1 cap placebo/day for 6 month
Study: NCT02514421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroporation
Description: Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: The chemotherapy schedule will include administration of gemcitabine 1000mg/m2 IV infusion over approximately 30 minutes on days 1, 8, and 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: The chemotherapy schedule will include administration of nab-paclitaxel 125mg/m2 intravenous (IV) over approximately 30 to 45 minutes on Days 1, 8, and 15.
Study: NCT02654990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat Capsules
Description: 20 mg, 10 mg or 15 mg (for dose reductions only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat Capsules
Description: 20 mg, 10 mg or 15 mg (for dose reductions only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat Capsules
Description: 20 mg, 10 mg or 15 mg (for dose reductions only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib Injection
Description: 1.3 mg/square meter subcutaneous administration. Cycle 1-4: 2 weeks on/1 week off, BIW for participants ≤ 75 years at time of screening; once a week for participants \> 75 years. Cycle 5+: once a week for all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib Injection
Description: 1.3 mg/square meter subcutaneous administration. Cycle 1-4: 2 weeks on/1 week off, BIW for participants ≤ 75 years at time of screening; once a week for participants \> 75 years. Cycle 5+: once a week for all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib Injection
Description: 1.3 mg/square meter subcutaneous administration. Cycle 1-4: 2 weeks on/1 week off, BIW for participants ≤ 75 years at time of screening; once a week for participants \> 75 years. Cycle 5+: once a week for all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone tablets
Description: Pre and 24 hours after bortezomib administration. Participants ≤ 75 years at time of screening: 20 mg/dose participants; \> 75 years: 10 mg/dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone tablets
Description: Pre and 24 hours after bortezomib administration. Participants ≤ 75 years at time of screening: 20 mg/dose participants; \> 75 years: 10 mg/dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone tablets
Description: Pre and 24 hours after bortezomib administration. Participants ≤ 75 years at time of screening: 20 mg/dose participants; \> 75 years: 10 mg/dose.
Study: NCT03339284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone sodium phosphate
Description: Dexamethasone injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Hydrocloride
Description: Ropivacaine injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Hydrocloride
Description: Ropivacaine injection
Study: NCT01662791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: All individuals in the weight loss group (i.e., only the Case group) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO BID for 14 days. Treatment will not depend upon the results of the bacterial overgrowth breath test. Thus, both normal and abnormal breath test subjects received antibiotic treatment.
Study: NCT03339284

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/mL
Description: Sodium Chloride injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 9mg/mL
Description: Sodium Chloride injection
Study: NCT01755143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging scan sequences of the head, neck, and chest
Study: NCT01468259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: The dose to be used is a single 600 mg dose (2 x 300 mg capsules) of droxidopa.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: The dose to be used is a single 600 mg dose (2 x 300 mg capsules) of droxidopa.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: The dose to be used is a single 600 mg dose (2 x 300 mg capsules) of droxidopa.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: The dose to be used is a single 600 mg dose (2 x 300 mg capsules) of droxidopa.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: The dose to be used is a single 600 mg dose (2 x 300 mg capsules) of droxidopa.
Study: NCT04036435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days
Study: NCT01828983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone support groups

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education webinars
Study: NCT03554395

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Gastric cancer
Description: CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study: NCT04115592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa butter
Description: Consumption of cocoa butter made with chocolate confectionery
Study: NCT01755143

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pacemaker System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker System
Study: NCT04115592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa butter oleogel
Description: Consumption of cocoa butter oleogel made with chocolate confectionery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sal seed oil
Description: Consumption of sal seed oil made with chocolate confectionery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sal seed oleogel
Description: Consumption of sal seed oleogel made with chocolate confectionery
Study: NCT01911481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hydration
Study: NCT02557802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluenz Tetra
Description: Intranasal spray, 0.2 ml dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluenz Tetra
Description: Intranasal spray, 0.2 ml dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix Tetra
Description: Intramuscular injection, 0.5 ml dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix Tetra
Description: Intramuscular injection, 0.5 ml dose
Study: NCT01415817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training session
Description: Series of two training sessions after the first phase of study followed by monthly feedback.
Study: NCT00895622

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 54 Gy radiotherapy
Description: External beam radiation therapy (EBRT) to a total dose of 54 Gy (RBE) in 30 fractions. 1.8 Gy (RBE) daily, 5 fractions per week, excluding weekends. 3D-CRT or IMRT or Proton allowed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 60 Gy radiotherapy
Description: External beam radiation therapy using intensity-modulated radiation therapy (IMRT) to a total dose of 60 Gy in 30 fractions. 2.0 Gy daily, 5 fractions per week, excluding weekends.
Study: NCT00377286

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine (a dietary supplement)
Description: 1500 mg in 16 oz lite lemonade, once per day for 6 months
Study: NCT00926848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partners Together in Health (PaTH) Intervention
Description: Patients and partners in the PaTH experimental group participated in 18-36 exercise and 18 educational sessions in a structured cardiac rehabilitation program. Patients in the Usual care group also participated in 18-36 exercise and 18 educational sessions; partners, however, only participated in the educational sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Partners Together in Health (PaTH) Intervention
Description: Patients and partners in the PaTH experimental group participated in 18-36 exercise and 18 educational sessions in a structured cardiac rehabilitation program. Patients in the Usual care group also participated in 18-36 exercise and 18 educational sessions; partners, however, only participated in the educational sessions.